WHAT
IS ESPýOC?

ESPýOC™ is a game changer in the way the dental and medical community visualizes oral cancer. ESPýOC™ is a simple, cost effective and non-invasive chair-side test that provides important screening information for patients with suspicious lesions. Utilizing UV Autofluorescence and a unique patent pending biomarker approach, ESPýOC™ demonstrated 100% sensitivity and 85% specificity for oral cancer detection in over 120 patients. ESPýOC™ never failed to detect a cancer and accurately detected 74% of precancerous lesions.

WHO
CREATED IT?

Visual Solutions, (a wholly owned subsidiary of Inter-Med and Vista Dental Products) is focused on developing transformative life changing technologies for cancer screening, detection and intervention through the use of molecular markers. Drawing on nine years of research, development and clinical studies, we are proud to bring to market the ESPýOC™ oral cancer screening system.

HOW
DOES IT WORK?

Visual Solutions’ patent pending device incorporates UV auto fluorescence technology along with fluorescent stains / molecular probes to highlight diseased lesions in the oral cavity. The fluorescent stains identify high nuclear content areas while the molecular probe targets abnormal glycosylation, which is a property universal to carcinogenesis. By targeting DNA/RNA rich areas and cell surface tumor related glycan signatures the device provides a mechanism for early identification and surveillance of oral cancerous and precancerous lesions.

TECHNOLOGY

CLINICAL STUDIES

CLINICAL STUDIES

We’ve done the research so you don’t have to. In university supervised double-blinded clinical trials, ESPýOC™ had the lowest false positive and false negative rates of any oral cancer-screening product on the market today.

COMPETITIVE RESULTS

COMPETITIVE RESULTS

The proof is in the numbers. When placed side-by-side with the industry’s leading competitors, ESPýOC™ out performed each of them. You can’t argue with 74% detection of precancer and 100% detection of oral cancer.